N-T-Butoxycarbonyl-S-[2-Nitro-1-(2-Thienyl)Ethyl]-L-Cysteine置于palladium On Activated Charcoal N-甲基吗啉,盐酸,叠氮磷酸二苯酯,氢气,Sodium Hydride,溶剂黄146,三乙胺体系中,用 1,4-二氧六环,二氯甲烷,N,N-二甲基甲酰胺 用作溶剂,25.0~70.0 °C,303.98 Kpa 条件下,反应 62.0H,反应生成盐酸替莫普利 参考文献:Angiotensin-Converting Enzyme Inhibitors. Perhydro-1,4-Thiazepin-5-One Derivatives 标题:Angiotensin-Converting Enzyme Inhibitors. Perhydro-1,4-Thiazepin-5-One Derivatives 摘要:Alpha-[6-[[(S)-1-(Ethoxycarbonyl)-3-Phenylpropyl]Amino]-5-Oxoperhydro-1,4-Thiazepin-4-Yl]Acetic Acids (Monoester Monoacids) And Their Dicarboxylic Acids Having The Hydrophobic Substituents At The 2-Or 3-Position Of The Thiazepinone Ring Were Prepared And Assayed For Angiotensin-Converting Enzyme (Ace) Inhibitory Activity. The Dicarboxylic Acids Having The Pseudoequatorial Amino Groups At The 6-Position And The Pseudoequatorial Hydrophobic Substituents At The 2-Or 3-Position Of The Chair Conformation Of The Thiazepinone Ring Had Potent In Vitro Inhibitory Activity. The Monoester Monoacids Having The Hydrophobic Substituents At The 2-Position Suppressed Pressor Response To Angiotensin I For A Longer Duration Than Those Having The Substituents At The 3-Position When Administered Orally. The Structure-Activity Relationship Was Studied By Conformational Energy Calculations Of The Thiazepinone Ring. Doi:10.1021/jm00394A009
1: No effects on sleep of a histamine H1-receptor antagonist: temelastine. K Adam, I Oswald Br J Clin Pharmacol. 1986 Dec; 22(6): 718–720. doi: 10.1111/j.1365-2125.1986.tb02963.x L Shall, R Marks Br J Clin Pharmacol. 1987 Oct; 24(4): 409–413. doi: 10.1111/j.1365-2125.1987.tb03192.x B G Charles, J J Schneider, R L Norris, P J Ravenscroft Br J Clin Pharmacol. 1987 Nov; 24(5): 673–675. doi: 10.1111/j.1365-2125.1987.tb03229.x E. A. Brown, R. Griffiths, C. A. Harvey, D. A. Owen Br J Pharmacol. 1986 Mar; 87(3): 569–578. doi: 10.1111/j.1476-5381.1986.tb10199.x S. Hishinuma, J. M. Young Br J Pharmacol. 1995 Nov; 116(6): 2715–2723. doi: 10.1111/j.1476 5381.1995.tb17232.x W. J. Gibson, T. W. Roques, J. M. Young Br J Pharmacol. 1994 Apr; 111(4): 1262–1268. doi: 10.1111/j.1476 5381.1994.tb14882.x J. A. Arias-Montaño, V. Berger, J. M. Young Br J Pharmacol. 1994 Feb; 111(2): 598–608. doi: 10.1111/j.1476-5381.1994.tb14779.x J. M. Treherne, J. S. Stern, W. J. Flack, J. M. Young Br J Pharmacol. 1991 Jul; 103(3): 1745–1751. doi: 10.1111/j.1476-5381.1991.tb09857.x J. M. Treherne, J. M. Young Br J Pharmacol. 1988 Jul; 94(3): 797–810. doi: 10.1111/j.1476-5381.1988.tb11591.x 2014 Jan; 17(1): 55–61. PMCID: PMC3938887
合成参考文献
参考文献:10.1248/bpb.b17-00880 摘要:Ishizaki Y, Furihata T, Oyama Y, Ohura K, Imai T, Hosokawa M, Akita H, Chiba K. Development of a Caco-2 Cell Line Carrying the Human Intestine-Type CES Expression Profile as a Promising Tool for Ester-Containing Drug Permeability Studies. Biological & Pharmaceutical Bulletin. 2018 May 01;41(5):697–706. doi: 10.1248/bpb.b17-00880. 参考文献:10.1291/hypres.26.907 摘要:Yoshida K, Kawamura T, Xu HL, Ji L, Mori N, Kohzuki M. Effects of exercise training on glomerular structure in fructose-fed spontaneously hypertensive rats. Hypertens Res. 2003 Nov;26(11):907–14. doi: 10.1291/hypres.26.907. 参考文献:10.1097/00005344-199409000-00017 摘要:Delacrétaz E, Nussberger J, Püchler K, Wood AJ, Robinson PR, Waeber B, Brunner HR. Value of Different Clinical and Biochemical Correlates to Assess Angiotensin Converting Enzyme Inhibition. Journal of Cardiovascular Pharmacology. 1994 Sep;24(3):479–85. doi: 10.1097/00005344-199409000-00017. 参考文献:10.1161/01.hyp.29.1.286 摘要:Iwatsubo H, Nagano M, Sakai T, Kumamoto K, Morita R, Higaki J, Ogihara T, Hata T. Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension. 1997 Jan;29(1 Pt 2):286–90. doi: 10.1161/01.hyp.29.1.286.